<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360174</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-Protocol-0045</org_study_id>
    <nct_id>NCT04360174</nct_id>
  </id_info>
  <brief_title>CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Prospective, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability and efficacy of a single sustained release dose of
      OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle
      glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, open label study, to evaluate the safety, tolerability
      and efficacy of OTX-TIC intracameral implant in subjects with primary open-angle glaucoma or
      ocular hypertension. The subjects will be followed for approximately 7 months (one-month
      washout and 6 months follow-up after injected of the OTX-TIC implant).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential: Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events for each subject</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>All adverse events will be captured throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>Diurnal IOP [Time Frame: 2 Week Visit]</time_frame>
    <description>IOP measurements at 8 am, 10 am, and 4 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>Diurnal IOP [ 6 Week Visit]</time_frame>
    <description>IOP measurements at 8 am, 10 am, and 4 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>Diurnal IOP [12 Week Visit]</time_frame>
    <description>IOP measurements at 8 am, 10 am, and 4 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>Diurnal IOP [4 Months Visit]</time_frame>
    <description>IOP measurements at 8 am, 10 am, and 4 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>Diurnal IOP [6 Months Visit]</time_frame>
    <description>IOP measurements at 8 am, 10 am, and 4 pm</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>OTX-TIC-Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 µg (formulation1) implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OTX-TIC-Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>26 µg (formulation1) implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OTX-TIC-Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 µg (formulation 2) implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OTX-TIC-Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 µg (formulation 3) implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TIC</intervention_name>
    <description>OTX-TIC implant is injection in the anterior chamber of the eye</description>
    <arm_group_label>OTX-TIC-Cohort 1</arm_group_label>
    <arm_group_label>OTX-TIC-Cohort 2</arm_group_label>
    <arm_group_label>OTX-TIC-Cohort 3</arm_group_label>
    <arm_group_label>OTX-TIC-Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a documented diagnosis of ocular hypertension or primary open-angle glaucoma

          -  Have IOP that is currently controlled as assessed by the Investigator

          -  Have open, normal appearing anterior chamber angles as determined by gonioscopy

        Exclusion Criteria:

          -  Have closed angle glaucoma, narrow angle glaucoma, pseudoexfoliation syndrome,
             pseudoexfoliation glaucoma, pigment dispersion or pigmentary glaucoma, glaucoma
             diagnosis prior to 15 years of age, inflammatory, neovascular or other secondary

          -  Have a known or suspected allergy and/or hypersensitivity to a prostaglandin (i.e.
             travoprost), fluorescein or to any component of the study products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>781-357-4000</phone>
    <email>clinicalaffairs@ocutx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ocular Therapeutix</last_name>
      <phone>781-357-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ocular Therapeutix</last_name>
      <phone>781-357-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ocular Therapeutix</last_name>
      <phone>781-357-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ocular Therapeutix</last_name>
      <phone>781-357-4000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

